Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Progress in Prostate Cancer (at Last!).

Glodé LM.

Oncology (Williston Park). 2015 Jun;29(6):407, 414. No abstract available.

3.
4.

Chemotherapy for prostate cancer.

Wang J, Waxman J.

Clin Oncol (R Coll Radiol). 2001;13(6):453-4. No abstract available.

PMID:
11824885
5.

ESMO 2014: new trends in precision medicine.

Morere JF, Innominato P.

Target Oncol. 2014 Dec;9(4):293-4. doi: 10.1007/s11523-014-0348-3. No abstract available.

PMID:
25503266
6.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.

J Clin Oncol. 2015 Mar 1;33(7):786-809. doi: 10.1200/JCO.2014.59.9746. Review. No abstract available.

PMID:
25605863
7.

Experimental models for the development of new medical treatments in prostate cancer.

Chauchereau A.

Eur J Cancer. 2011 Sep;47 Suppl 3:S200-14. doi: 10.1016/S0959-8049(11)70166-6. Review. No abstract available.

PMID:
21943976
8.

Chemotherapy of hormone refractory prostatic cancer.

Stoter G, Jones WG.

Prog Clin Biol Res. 1988;260:123-5. Review. No abstract available.

PMID:
3129730
9.

Systemic therapeutic strategies for prostate cancer.

Nelson WG.

Clin Adv Hematol Oncol. 2005 Aug;3(8):619-21. No abstract available.

PMID:
16167046
10.

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.

Armstrong AJ.

Oncology (Williston Park). 2014 Oct;28(10):881, 883. No abstract available.

11.

[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].

[No authors listed]

Aktuelle Urol. 2005 Sep;36(5):385-7. German. No abstract available.

PMID:
16163602
12.

Poxviral-based prostate-specific antigen vaccine in prostate cancer.

León L, Areses MC, Anido U, Gómez A, Carballo AM.

J Clin Oncol. 2010 Aug 20;28(24):e416; author reply e417. doi: 10.1200/JCO.2010.29.1070. No abstract available.

PMID:
20566998
13.

Optimal timing of chemotherapy in androgen independent prostate cancer.

Schnadig ID, Beer TM.

Urol Oncol. 2009 Jan-Feb;27(1):97-100. doi: 10.1016/j.urolonc.2008.04.004. Review.

PMID:
19111808
14.

Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. June 2004.

Lee D, Price N, Reddy K.

Clin Prostate Cancer. 2004 Sep;3(2):73-6. No abstract available.

PMID:
15479487
15.
16.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919.

PMID:
22147736
17.

Repurposing to fight cancer: the metformin-prostate cancer connection.

Azvolinsky A.

J Natl Cancer Inst. 2014 Feb;106(2):dju030. doi: 10.1093/jnci/dju030. No abstract available.

PMID:
24511112
18.

Highlights from the 39th Annual meeting of the American Society of Clinical Oncology Chicago, Illinois.

Tyagi P, Klem J, D'Orazio A.

Clin Prostate Cancer. 2003 Sep;2(2):73-9. No abstract available.

PMID:
15040866
19.

New drugs and treatment strategies in prostate cancer.

Galsky MD.

Clin Adv Hematol Oncol. 2014 Jan;12(1):51-3. No abstract available.

PMID:
25000316
20.
Items per page

Supplemental Content

Support Center